The European Medicines Agency (EMA),
which regulates new medicines for the
European Union, approved 38 medicines
containing new active substances in 2013.
This compared with the 35 novel medicines
approved in 2012. Europe also had the first
two approvals for biosimilar monoclonal
antibodies (mAbs).